Disruptions from Covid-19 pandemic have caused limited access to physicians for Pfizer’s marketing and sales teams have had. If ‘the novel Coronavirus pandemic hamstringing the company’s sales team,’ there could be a slowdown in new prescriptions and a sales hit in the second quarter, said the global … Continue reading
Tag Archives: commercial
Any Threat To Current Commercial Model Of ‘Gene Therapy’?
Wish All My Readers A Very Happy, Healthy, Peaceful and Prosperous 2020 One of the most complex areas in disease management, is the ailments related to genetic disorders. As these were incurable, over the last four decades, medical researchers … Continue reading
Reaping Rich Harvest With Orphan Drugs
A set of perplexing questions on the drug industry has been haunting many, since long. One such area is intimately associated with the core purpose of this business, as enunciated by each company, often publicly. Just to give a feel … Continue reading
Is India A Success Story With Biosimilar Drugs?
How Indian generic companies are expanding, if not shifting their business focus on biosimilar and complex generic drugs, may be a current trend of general discourse – but the initiative is not a current one. This journey commenced decades ago … Continue reading
Transparency in Drug Trial Data: Thwarted by Lobbyists or Embroiled in Controversy?
Based on a leaked letter from overseas pharma industry bodies, a leading international daily in late July 2013 reported: “Big pharma mobilizing patients in battle over drugs trials data.” Some experts consider it as a poignant, if not a bizarre … Continue reading
Pharma Marketing in India: 10 Chain Events to Catalyze a Paradigm Shift
In the matured markets of the world pharmaceutical marketing is quite different in many respect as compared to India. Besides doctors, different sets of customer groups like, healthcare providers, patient advocacy groups, pharmacy benefit managers, clinical assessment authorities play various … Continue reading
Biosimilar Drugs -A raging scientific debate with mounting global commercial interest
On December 11, 2008, Reuters reported that two days after Merck & Co. announced a major push into generic versions of biotechnology medicines, Eli Lilly & Co. signaled similar aspirations. This report raised many eyebrows in the global pharmaceutical industry, … Continue reading